Past appeals and decisions
TA ID TBC Afamelanotide for erythropoietic protoporphyria ID927
Appeal hearing date 15 May 2023
Appeal hearing date 3 September 2020
TA ID TBC Afamelanotide for treating erythropoietic protoporphyria
Appeal hearing date 30 July 2018
TA ID TA111 Alzheimer´s disease - donepezil, rivastigmine, galantamine and memantine (review)
Appeal hearing date 13-14 August 2006
TA ID TA142 Anaemia (cancer-treatment induced) - Erythropoetin (alpha and beta) and darbepoetin
Appeal hearing date 2 June 2006
TA ID TA143 Ankylosing spondylitis - adalimumab, etanercept & infliximab
Appeal hearing date 31 March 2008
TA ID TA010 Asthma (children under 5) - inhaler devices
Appeal hearing date 31 August 2000
TA ID TA138 Asthma (in adults) - corticosteroids
Appeal hearing date 9 January 2008
TA ID TA038 Asthma (older children) - inhaler devices
Appeal hearing date 13 February 2002
TA ID TA249 Atrial fibrillation - dabigatran etexilate
Appeal hearing date 7 February 2012
Appeal hearing date 25 September 2005
Appeal hearing date 28 September 2021
TA ID TA926 Baricitinib for treating severe alopecia areata
Appeal hearing date 12 September 2023
Appeal hearing date 3 May 2000
TA ID TA054 Breast cancer - vinorelbine
Appeal hearing date 15 August 2002
TA ID TBC Breast cancer (advanced or metastatic) - lapatinib
Appeal hearing date 8 June 2009
TA ID TBC Breast cancer (advanced or metastatic) - lapatinib (second appeal
Appeal hearing date 17 August 2010
TA ID TA107 Breast cancer (early) - trastuzumab
Appeal hearing date 26 July 2006
Appeal hearing date 23 May 2011
TA ID TA006 Breast cancer - taxanes
Appeal hearing date 14 June 2000
TA ID TA250 Breast cancer - eribulin
Appeal hearing date 13 February 2012
Appeal hearing date 13 October 2014
Appeal hearing date 19 September 2023
TA ID TA033 Colorectal cancer - Irinotecan, oxaliplatin and raltitrexed
Appeal hearing date 23 May 2001
TA ID TA033 Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed
Appeal hearing date 8 January 2002
TA ID TA307 Colorectal cancer (metastatic) – aflibercept
Appeal hearing date 23 January 2014
TA ID TA118 Colorectal cancer (metastatic) - bevacizumab & cetuximab
Appeal hearing date 27 November 2006
TA ID TA102 Conduct disorder in children - parent-training/education programmes
Appeal hearing date 21 April 2006
TA ID TA152 Coronary artery stents - drug-eluting stents
Appeal hearing date 14 April 2008
TA ID TA051 Depression and anxiety - computerised cognitive behaviour therapy (CCBT)
Appeal hearing date 19 July 2002
TA ID TA097 Depression and anxiety - computerised cognitive behavioural therapy (CCBT)(review)
Appeal hearing date 17 November 2005
TA ID TA151 (review TA57) Diabetes - insulin pump therapy (review)
Appeal hearing date 16 May 2008
TA ID TA063 Diabetes (Type 2) - glitazones (review)
Appeal hearing date 2 June 2003
TA ID TA459 Dupuytren's contracture - collagenase clostridium histolyticum
Appeal hearing date 30 November 2015
TA ID TA007 Dyspepsia - proton pump inhibitors
Appeal hearing date 29 June 2000
TA ID TA059 Dupuytren's contracture - collagenase clostridium histolyticum
Appeal hearing date 12 February 2003
TA ID TA076 Epilepsy (adults) - newer drugs
Appeal hearing date 19 January 2004
TA ID TBC Erenumab for treating migraine
Appeal hearing date 4 December 2019
TA ID TA854 Esketamine for treatment-resistant depression ID1414
Appeal hearing date 27 July 2022
TA ID TA067 Flu (prophylaxis) - amantadine and oseltamivir
Appeal hearing date 19 December 2002
TA ID TA759 Fostamatinib for treating persistent or chronic immune thrombocytopenia ID1087
Appeal hearing date 9 November 2021
TA ID TA064 Growth hormone deficiency (adults) - human growth hormone
Appeal hearing date 20 August 2002
TA ID TA064 Growth hormone deficiency (adults) - human growth hormone
Appeal hearing date 3 July 2003
TA ID TA145 Head and neck cancer - cetuximab
Appeal hearing date 22 August 2007
TA ID TA008 Hearing disability - hearing aids
Appeal hearing date 21 July 2000
TA ID TA166 Hearing impairment - cochlear implants
Appeal hearing date 26 November 2008
TA ID TA189 Hepatocellular carcinoma (advanced and metastatic)- sorafenib
Appeal hearing date 26 February 2010
TA ID TA018 Hernia (inguinal) - laparoscopic surgery
Appeal hearing date 7 December 2000
TA ID TA002 Hip disease - replacement prostheses
Appeal hearing date 31 March 2000
TA ID TA164 Hyperuricaemia - febuxostat
Appeal hearing date 29 October 2008
TA ID TA504 Idiopathic pulmonary fibrosis - pirfenidone
Appeal hearing date 2 December 2016,and 1 December 2017
TA ID TA501 Intrabeam radiotherapy system for adjuvant treatment of early breast cancer
Appeal hearing date 8 December 2017
TA ID TA482 Kidney transplantation (adults) - immunosuppressive therapy (review)
Appeal hearing date 30 March 2016
TA ID TA482 Kidney transplantation (children, adolescents) - immunosuppressive regimens (review)
Appeal hearing date 30 March 2016
TA ID TA541 Leukaemia (acute lymphoblastic, relapsed, adults) - inotuzumab ozogamicen
Appeal hearing date 3 November 2017
TA ID TA193 Leukaemia (chronic lymphocytic, relapsed) - rituximab
Appeal hearing date 25 May 2010
Appeal hearing date 4 November 2011
TA ID TA162 Lung cancer (non-small cell) - Erlotonib
Appeal hearing date 6 June 2007
Appeal hearing date 16 May 2011
TA ID TA124 Lung cancer (non-small cell) - pemetrexed
Appeal hearing date 6 June 2007
TA ID TBC Lysosomal acid lipase deficiency - sebelipase alfa
Appeal hearing date 25 April 2017
TA ID TA068 Macular degeneration (age-related) - photodynamic therapy
Appeal hearing date 17 March 2003
TA ID TA155 Macular degeneration (age-related) - ranibizumab and pegaptanib
Appeal hearing date 30 June 2008
TA ID TA237 Macular oedema (diabetic) - ranibizumab: appeal
Appeal hearing date 4 October 2011
TA ID TA078 Menorrhagia - endometrial ablation
Appeal hearing date 26 January 2004
TA ID TA135 Mesothelioma - Pemetrexed disodium
Appeal hearing date 27 October 2006
TA ID TA754 Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome ID1405
Appeal hearing date 11 May 2021
TA ID TA020 Motor neurone disease - riluzole
Appeal hearing date 4 January 2001
TA ID TA129 Multiple myeloma - Bortezomib
Appeal hearing date 8 February 2007
TA ID TA228 Multiple myeloma (first line) - bortezomib and thalidomide
Appeal hearing date 15 November 2010
TA ID TA032 Multiple sclerosis - beta interferon and glatiramer
Appeal hearing date 22-23 September 2000
TA ID TA032 Multiple sclerosis - beta interferon and glatiramer acetate
Appeal hearing date 26 November 2001
TA ID TA218 Myelodysplastic syndrome - azacitidine
Appeal hearing date 1 June 2010
TA ID TBC Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy)
Appeal hearing date 30 September 2016
Appeal hearing date 12 December 2017
TA ID ID3913 Olipudase alfa for treating Niemann-Pick disease types A and B
Appeal hearing date 24 May 2024
TA ID TA621 Osimertinib for untreated EGFR-positive non-small-cell lung cancer
Appeal hearing date 30 September 2019
TA ID TA027 Osteoarthritis and rheumatoid arthritis - cox II inhibitors
Appeal hearing date 7 June 2001
TA ID TA160 Osteoporosis - primary prevention
Appeal hearing date 22 October 2007
TA ID TA160 Osteoporosis - primary prevention
Appeal hearing date 15 September 2008
TA ID TA087 Osteoporosis - secondary prevention
Appeal hearing date 22 October 2004
TA ID TA161 Osteoporosis - secondary prevention including strontium ranelate
Appeal hearing date 22 October 2007
TA ID TA161 Osteoporosis - secondary prevention including strontium ranelate
Appeal hearing date 15 September 2008
TA ID TA055 Ovarian cancer - paclitaxel (review)
Appeal hearing date 12 November 2002
Appeal hearing date 24 April 2015
Appeal hearing date 16 March 2015
Appeal hearing date 23 June 2020
Appeal hearing date 23 November 2007
TA ID TA103 Psoriasis - efalizumab and etanercept
Appeal hearing date 27 January 2006
TA ID TA104 Psoriatic arthritis - etanercept and infliximab
Appeal hearing date 20 February 2006
TA ID TA104 Psoriatic arthritis (active) - apremilast (after-DMARDs)
Appeal hearing date 6 November 2015
TA ID TA255 Prostate cancer - cabazitaxel
Appeal hearing date 22 March 2012
TA ID TA352 Prostate cancer (advanced, hormone dependent) - degarelix depot ID590
Appeal hearing date 12 November 2014
TA ID TA832 Macular degeneration (age-related) - photodynamic therapy
Appeal hearing date 7 September 2022
TA ID TA178 Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus
Appeal hearing date 13 July 2009
TA ID TA333 Renal cell carcinoma, locally advanced and/or metastatic (2ndline) - axitinib ID518
Appeal hearing date 10 June 2013
TA ID TA219 Renal cell carcinoma (second line metastatic) - everolimus
Appeal hearing date 28 February 2011
TA ID TA085 Renal transplantation - immuno-suppressive regimens (adults)
Appeal hearing date 26 April 2004
TA ID TA130 Rheumatoid arthritis - Adalimumab, etanercept and infliximab
Appeal hearing date 4 April 2007
TA ID TA072 Rheumatoid arthritis - anakinra
Appeal hearing date 18 September 2003
Appeal hearing date 26 November 2015
TA ID TA141 Rheumatoid arthritis (refractory) - abatacept
Appeal hearing date 17 March 2008
TA ID TA037 Rituximab for follicular lymphoma
Appeal hearing date 21 May 2001
TA ID TA043 Schizophrenia - Atypical antipsychotic
Appeal hearing date 24 April 2002
TA ID TA397 Systemic lupus erythematosus (active) - belimumab
Appeal hearing date 18 July 2012
TA ID TA696 Tafamidis for treating transthyretin amyloid cardiomyopathy
Appeal hearing date 4-5 March 2021
Appeal hearing date 14 November 2022
TA ID TA272 Transitional cell carcinoma of the urothelial tract - vinflunine
Appeal hearing date 23 May 2011
TA ID TA090 Vascular disease - clopidogrel and dipyridamole
Appeal hearing date 25 February 2005
Rejected appeals
TA ID TA201 Asthma (in children) - omalizumab
TA265 Bone metastases from solid tumours - denosumab
TA209 Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (review)
GID-HST10008 Neuronal ceroid lipofuscinosis type 2 - cerliponase alfa (Biomarin) [ID943]
TA316 Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel)
TA272 Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine